Payment overview · 2025
General Payments
$203.78
12 reported records · 7 companies
Healthcare provider profile · identity verified
Judith Ann Brown, MD
Allopathic & Osteopathic Physicians|Family Medicine · TUCSON, AZ · NPI 1639137417
Verified facts
What the public records show
CMS Open Payments records show Judith Ann Brown, MD received $203.78 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.03 | 25.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.28 | 22.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.10 | 18.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.89 | 10.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.93 | 8.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.03 | 7.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.52 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $203.78 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.28 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 675 | 190 |
| Atorvastatin Calcium | Atorvastatin Calcium | 559 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 529 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 119 |
| Losartan Potassium | Losartan Potassium | 338 | 102 |
| Lisinopril | Lisinopril | 300 | 101 |
| Omeprazole | Omeprazole | 239 | 75 |
| Ezetimibe | Ezetimibe | 180 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 51 |
| Simvastatin | Simvastatin | 173 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 159 | 55 |
| Gabapentin | Gabapentin | 159 | 63 |
| Montelukast Sodium | Montelukast Sodium | 137 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 50 |
| Tramadol Hcl | Tramadol Hcl | 113 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 31 |
| Trazodone Hcl | Trazodone Hcl | 107 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 21 |
| Alprazolam | Alprazolam | 87 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 28 |
| Mounjaro | Tirzepatide | 82 | 11 |
| Sertraline Hcl | Sertraline Hcl | 81 | 23 |
| Famotidine | Famotidine | 79 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 26 |
| Metformin Hcl | Metformin Hcl | 76 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 25 |
| Potassium Chloride | Potassium Chloride | 74 | 24 |
| Estradiol | Estradiol | 73 | 21 |
| Carvedilol | Carvedilol | 69 | 21 |
| Meloxicam | Meloxicam | 68 | 36 |
| Alendronate Sodium | Alendronate Sodium | 63 | 26 |
| Metformin Hcl Er | Metformin Hcl | 59 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 11 |
| Bupropion Xl | Bupropion Hcl | 53 | 20 |
| Ozempic | Semaglutide | 51 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 13 |
| Methylprednisolone | Methylprednisolone | 48 | 43 |
| Furosemide | Furosemide | 46 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 12 |
| Valsartan | Valsartan | 45 | 14 |
| Synthroid | Levothyroxine Sodium | 44 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 34 |
| Ibandronate Sodium | Ibandronate Sodium | 37 | 15 |
| Allopurinol | Allopurinol | 36 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 13 |
| Lorazepam | Lorazepam | 35 | 18 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Prednisone | Prednisone | 34 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | 12 |
| Eliquis | Apixaban | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 21 |
| Baclofen | Baclofen | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 14 |
| Azelastine Hcl | Azelastine Hcl | 29 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Diazepam | Diazepam | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Testosterone | Testosterone | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $203.78 · 12 records | ABBVIE INC. | AIRSUPRA, FREESTYLE LIBRE 3, Kerendia, OTEZLA, QULIPTA, REPATHA, SHINGRIX, UBRELVY, VRAYLAR, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error